Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) Return on Sales (2018 - 2025)

Cue Biopharma's Return on Sales history spans 8 years, with the latest figure at 3.4% for Q3 2025.

  • For Q3 2025, Return on Sales fell 86.0% year-over-year to 3.4%; the TTM value through Sep 2025 reached 5.24%, down 68.0%, while the annual FY2024 figure was 4.29%, 472.0% up from the prior year.
  • Return on Sales for Q3 2025 was 3.4% at Cue Biopharma, down from 2.86% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.96% in Q4 2021 and bottomed at 507.96% in Q2 2022.
  • The 5-year median for Return on Sales is 7.05% (2024), against an average of 49.46%.
  • The largest annual shift saw Return on Sales tumbled -50421bps in 2022 before it surged 49860bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 0.96% in 2021, then tumbled by -9763bps to 94.26% in 2022, then surged by 92bps to 7.1% in 2023, then increased by 17bps to 5.93% in 2024, then soared by 43bps to 3.4% in 2025.
  • Per Business Quant, the three most recent readings for CUE's Return on Sales are 3.4% (Q3 2025), 2.86% (Q2 2025), and 28.81% (Q1 2025).